logo

For the Inventor, By the Inventor

Berkeley, CA, United States of America

Caribou Biosciences, Inc.


USPTO Granted Patents = 57



Trademarks = 9

Forward Citations = 534

Loading Chart...
Loading Chart...

29 inventors (with patents filed for the assignee):

goldMedal Andrew Paul May (37 out of 69 patents)

silverMedal Paul Daniel Donohoue (32 out of 45 patents)

bronzeMedal Rachel E Haurwitz (11 out of 15 patents)

4.  Jennifer A Doudna (8 out of 138 patents)

5.  James M Berger (8 out of 8 patents)

6.  Matthew Merrill Carter (8 out of 14 patents)

7.  Peter Sean Cameron (8 out of 9 patents)

8.  John Van Der Oost (7 out of 21 patents)

9.  Lijun Wu (7 out of 21 patents)

10.  Vita Golubovskaya (7 out of 18 patents)

11.  Sanne Eveline Klompe (7 out of 9 patents)

12.  Samuel Henry Sternberg (6 out of 9 patents)

13.  Stan Johan Jozef Brouns (5 out of 5 patents)

14.  Megan Van Overbeek (2 out of 2 patents)

15.  Daniël Christianus Swarts (2 out of 2 patents)


Core Competencies:
Humanized BCMA Antibody
BCMA-CAR-T Cells
CRISPR Endonuclease
Engineered Cascade Components
Nucleic Acid-Targeting Nucleic Acids
ROR1-Targeting Engineered Cells
Hybrid DNA/RNA Polynucleotides
DNA Repair
CRISPR-Cas9 Systems
Natural Killer Cells
Modified Cascade Ribonucleoproteins
Argonaute Technology

57 patents:

1. 12435152 - Humanized BCMA antibody and BCMA-CAR-T cells (2025-10-07),
2. 12416045 - Method of capturing CRISPR endonuclease cleavage products (2025-09-16),
3. 12227776 - Engineered cascade components and cascade complexes (2025-02-18),
4. 11939604 - Modified cascade ribonucleoproteins and uses thereof (2024-03-26),
5. 11932703 - Anti-ROR1 antibody and ROR1-targeting engineered cells (2024-03-19),
6. 11555181 - Engineered cascade components and cascade complexes (2023-01-17),
7. 11505808 - Engineered nucleic acid-targeting nucleic acids (2022-11-22),
8. 11472884 - Humanized BCMA antibody and BCMA-CAR-T cells (2022-10-18),
9. 11459588 - Methods of use of CRISPR CPF1 hybrid DNA/RNA polynucleotides (2022-10-04),
10. 11312953 - Compositions and methods of nucleic acid-targeting nucleic acids (2022-04-26),
11. 11299549 - Humanized BCMA antibody and BCMA-CAR-T cells (2022-04-12),
12. 11236364 - CRISPR hybrid DNA/RNA polynucleotides and methods of use (2022-02-01),
13. 11225649 - Engineered nucleic-acid targeting nucleic acids (2022-01-18),
14. 11155814 - Methods for using DNA repair for cell engineering (2021-10-26),
15. 11142583 - BCMA-CAR-natural killer (NK) cells and methods related thereto (2021-10-12),
Caribou Biosciences, Inc. is a leading company in CRISPR genome engineering. They develop innovative technologies and provide services to enable precise and efficient editing of genes. With their proprietary CRISPR-Cas9 genome editing technology, Caribou Biosciences is advancing breakthrough applications in various fields including therapeutics, agriculture, and industrial biotechnology.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

57 Patents

#9 in Berkeley, CA

#1,424 in California

#6,037 in US

#12,152 in the World

...
Berkeley, CA, United States of America

Caribou Biosciences, Inc.

Forward Citations = 534

29 inventors:

goldMedal Andrew Paul May (37 out of 69 patents)

silverMedal Paul Daniel Donohoue (32 out of 45 patents)

bronzeMedal Rachel E Haurwitz (11 out of 15 patents)

4.  Jennifer A Doudna (8 out of 138 patents)

5.  James M Berger (8 out of 8 patents)

Please report any incorrect information to support@idiyas.com
Loading…